Cardiff Oncology furnishes investor presentation with Phase 2 CRDF-004 interim results

Cardiff Oncology, Inc.

Presentation covers interim data from randomized Phase 2 CRDF-004 trial of onvansertib + SoC in first-line RAS-mutated mCRC.
Presentation also details registrational study plans for onvansertib in this indication.
No specific efficacy or safety endpoints were disclosed in the filing itself; details are in furnished Exhibit 99.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.